International Journal of Infertility & Fetal Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  15 (2024)
Volume  14 (2023)
Volume  13 (2022)
Volume  12 (2021)
Volume  11 (2020)
Volume  10 (2019)
Volume  9 (2018)
Volume  8 (2017)
Volume  7 (2016)
Volume  6 (2015)
Volume  5 (2014)
Volume  4 (2013)
Volume  3 (2012)
Volume  2 (2011)
Volume  1 (2010)
Related articles

VOLUME 2 , ISSUE 2 ( May-August, 2011 ) > List of Articles

REVIEW ARTICLE

Novel Therapies for Treating Short Stature with Congenital Adrenal Hyperplasia

Joe Leigh Simpson, Michael Christopher Hann, Anisha Kshetrapal, Maria I New

Citation Information : Simpson JL, Hann MC, Kshetrapal A, New MI. Novel Therapies for Treating Short Stature with Congenital Adrenal Hyperplasia. Int J Infertil Fetal Med 2011; 2 (2):45-50.

DOI: 10.5005/jp-journals-10016-1017

License: CC BY-NC 4.0

Published Online: 01-04-2014

Copyright Statement:  Copyright © 2011; The Author(s).


Abstract

Abbreviations

Congenital adrenal hyperplasia (CAH); Salt wasting (SW-CAH); Non-salt wasting (NSW-CAH); Growth hormone (GH); Gonadotropin releasing hormone analogs (GnRHa); Luteinizing hormone releasing hormone analog (LHRHa); 21-hydroxylase gene (CYP21); 21-hydroxylase pseudogene (CYP21p); Hypothalamic-pituitary-adrenal (HPA); Corticotropin-releasing hormone (CRH); Adrenocorticotropic hormone (ACTH); Bone mineral density (BMD); Standard score (SDS).

PDF Share
  1. Combination growth hormone and gonadotropin releasing hormone analog therapy in 11 betahydroxylase deficiency. J Pediatr Endocrinol Metab 2006;19: 855-57.
  2. Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2005;90:3318-25.
  3. Prolongation of growth by treatment of 11-hydroxylase deficiency with depotleuprolide, growth hormone, and hydrocortisone. J Pediatr Endocrinol Metab 2006;19:1251-55.
  4. Growth hormone therapy alone or in combination with gonadotropinreleasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001;86:1511-17.
  5. Growth and final height in classical and nonclassical 21-hydroxylase deficiency. J Endocrinol Invest 1989;12:91-95.
  6. Factors determining final height in congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 2001;14(Suppl 2):933-37.
  7. Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod Update 2004;10:469-85.
  8. Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency: Growth, development and therapeutic considerations. Endocrinol Metab Clin North Am 2001;30:193-206.
  9. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: A paradigm for prenatal diagnosis and treatment. Ann N Y Acad Sci 2010;1192:5-11.
  10. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: An evidence-based recommendation. J Clin Endocrinol Metab 2009;94:3882-88.
  11. Treatment and disease effects on short-term growth and adult height in children and adolescents with 21-hydroxylase deficiency. Klin Padiatr 1997;209:71-77.
  12. Dexamethasone treatment of virilizing congenital adrenal hyperplasia: The ability to achieve normal growth. Pediatrics 2000;106:767-73.
  13. Growth inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency: In early infancy and (pre)puberty. J Clin Endocrinol Metab 2003;88: 3525-30.
  14. Growth patterns and outcomes in congenital adrenal hyperplasia. Effect of chronic treatment regimens. NZ Med J 1995;108:311-14.
  15. Effect of treatment on growth in congenital adrenal hyperplasia. Indian J Pediatr 2000;67:783-89.
  16. The effect of treatment of final height in classical congenital adrenal hyperplasia (CAH). Acta Endocrinol Suppl (Copenh) 1986;279: 305-14.
  17. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: Deceleration of growth velocity during puberty. J Clin Endocrinol Metab 2007;92:1635-39.
  18. Experience with long-term glucocorticoid treatment in congenital adrenal hyperplasia: Growth pattern compared with genetic height potential. J Pediatr Endocrinol Metab 2006;19: 245-51.
  19. 17 alphahydroxyprogesterone— a salt-losing steroid: Relation to congenital adrenal hyperplasia. J Clin Endocrinol Metab 1961;21:909-22.
  20. Treatment of glucocorticoid-induced growth suppression with growth hormone. National Cooperative Growth Study. J Clin Endocrinol Metab 1998;83:2824-29.
  21. Bone density in young patients with congenital adrenal hyperplasia. Bone 1996;18:337-40.
  22. The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1997;82:3926-29.
  23. Effects of adrenal steroids on the bone metabolism of children with congenital adrenal hyperplasia. Ann NY Acad Sci 2007;1117:345-51.
  24. Bone mineral density and body composition in congenital adrenal hyperplasia. J Clin Endocrinol Metab 1995;80:2238-43.
  25. Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 1996;45:535-41.
  26. Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia. Pediatrics 1997;100:671-74.
  27. Growth in congenital adrenal hyperplasia. Indian J Pediatr 2006;73:89-93.
  28. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: A metaanalysis. J Pediatr 2001;138:26-32.
  29. A review of the effects of therapy on growth and bone mineralization in children with congenital adrenal hyperplasia. Growth hormone and IGF research: Official Journal of the Growth Hormone Research Society and the International IGF Research Society 2005;15(Suppl A):S26-30.
  30. Growth hormone prevents steroid-induced growth depression in health and uremia. Kidney Int 1991;40:1032-40.
  31. Adult height in women with early-treated congenital adrenal hyperplasia (21-hydroxylase type): Relation to body mass index in earlier childhood. Acta Paediatr 1995;84:899-903.
  32. Non-classical 21-hydroxylase deficiency in infancy and childhood: The effect of time of initiation of therapy on puberty and final height. Eur J Endocrinol 1997;136:188-95.
  33. Adult height and fertility in men with congenital virilizing adrenal hyperplasia. N Engl J Med 1978;299:1392-96.
  34. Growth and development: Congenital adrenal hyperplasia-glucocorticoids and height. Nat Rev Endocrinol 2010;6:14-15.
  35. Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia. J Pediatr 2002;141:247-52.
  36. Cas Lek Cesk 1995;134:689-91.
  37. The effect of therapy on mature height in congenital adrenal hyperplasia. J Clin Endocrinol Metab 1978;47:1320-24.
  38. Growth of patients with 21-hydroxylase deficiency: An analysis of the factors influencing adult height. Pediatr Res 1997;41:30-33.
  39. Growth pattern and final height in 21-hydroxylase deficiency. Indian Pediatr 2007;44:771-73.
  40. Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: The Italian experience. J Pediatr Endocrinol Metab 2003;16(Suppl 2):277-83.
  41. Regulation of hypothalamic somatostatin by glucocorticoids. J Steroid Biochem Mol Biol 1995;53:277-82.
  42. Auxological and biochemical parameters in assessing treatment of infants and toddlers with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Pediatr Endocrinol 1993;6:173-78.
  43. 11beta-hydroxylase deficiency: Improvement of final height with growth hormone and gonadotropin-releasing hormone analog. An Pediatr (Barc) 2007;67:153-56.
  44. Strategies for maximizing growth in puberty in children with short stature. Endocrinol Metab Clin North Am 2009;38:613-24.
  45. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: A randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab 2008;93:823-31.
  46. Sperm analysis in growth hormone-deficient adolescents previously treated with an aromatase inhibitor: Comparison with normal controls. Fertil Steril 2005;84:239-42.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.